Johnson & JohnsonNYSE: JNJ

WASHINGTON--(BUSINESS WIRE)--AHF Hails HRSA Stance on J&J's Illegal Attack on 340B Program.

A recent study, CARTITUDE-4, showed that CARVYKTI® can reduce the risk of death by 45% after three years in patients with relapsed or lenalidomide-refractory multiple myeloma. This makes CARVYKTI® the first cell therapy to improve overall survival compared to standard treatments for these patients. The findings were presented at the 2024 International Myeloma Society Annual Meeting, highlighting the potential of CARVYKTI® to change the treatment approach for multiple myeloma.

The rate of minimal residual disease (MRD) negativity at 10-5 more than doubled within 12 months when using DARZALEX FASPRO® in maintenance therapy, compared to lenalidomide alone. This led to an improvement in progression-free survival over 30 months. Johnson & Johnson shared these findings from three studies on the effectiveness of DARZALEX® and DARZALEX FASPRO® in maintenance treatments.

The first and only subcutaneous quadruplet treatment has shown a 60.9% improvement in minimal residual disease (MRD) negativity and a 43% decrease in the risk of progression or death. These findings were shared during a late-breaking presentation at the International Myeloma Society Annual Meeting in Rio de Janeiro. Johnson & Johnson reported that the Phase 3 CEPHEUS study highlighted the effectiveness of DARZALEX FASPRO® combined with bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma who are not eligible for a transplant.

Recently, Johnson & Johnson (JNJ) has caught the interest of users on Zacks.com. As a result, it's important to understand the factors that could influence the future of the stock.

Data from the Phase 1b RedirecTT-1 study show that the combination of TALVEY® and TECVAYLI® has a safety profile similar to each treatment used alone. Johnson & Johnson announced these updated results, highlighting high response rates and lasting effects in patients with relapsed or refractory multiple myeloma who had previously been treated with three different classes of drugs. This study is significant as it involves patients with extramedullary disease as well.

Recent data indicate a 100 percent overall response rate, with 56 percent of patients achieving a complete response or better when treated weekly. The safety profile, including infection rates, is comparable to the monotherapies TALVEY® and DARZALEX FASPRO®. Johnson & Johnson has shared updated findings from the Phase 1b TRIMM-2 study, which shows an 82 percent overall response rate for the combination of TALVEY®, DARZALEX FASPRO®, and pomalidomide in patients with relapsed or refractory multiple myeloma.

In the most recent trading session, Johnson & Johnson (JNJ) finished at $162.78, which is a decrease of 0.27% compared to the previous day.

We recommend that new investors stay away from purchasing JNJ's stock at this time because of the uncertainty related to its legal issues.